News | October 29, 2021
Laurus Labs PAT at Rs 201.90 cr. in Q2FY21
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
Marketed under the brand name DGJAJ, it helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country
Subscribe To Our Newsletter & Stay Updated
